TY - JOUR
T1 - Cutoff Values of MASK-air Patient-Reported Outcome Measures
AU - Sousa-Pinto, Bernardo
AU - S?-Sousa, Ana
AU - Vieira, Rafael Jos?
AU - Amaral, Rita
AU - Pereira, Ana Margarida
AU - Anto, Josep M.
AU - Klimek, Ludger
AU - Czarlewski, Wienczyslawa
AU - Mullol, Joaquim
AU - Pfaar, Oliver
AU - Bedbrook, Anna
AU - Brussino, Luisa
AU - Kvedariene, Violeta
AU - Larenas-Linnemann, Desir?e E.
AU - Okamoto, Yoshitaka
AU - Ventura, Maria Teresa
AU - Ansotegui, Ignacio J.
AU - Bosnic-Anticevich, Sinthia
AU - Canonica, G. Walter
AU - Cardona, Victoria
AU - Cecchi, Lorenzo
AU - Chivato, Tomas
AU - Cingi, Cemal
AU - Costa, El?sio M.
AU - Cruz, Alvaro A.
AU - del Giacco, Stefano
AU - Devillier, Philippe
AU - Fokkens, Wytske J.
AU - Gemicioglu, Bilun
AU - Haahtela, Tari
AU - Ivancevich, Juan Carlos
AU - Kuna, Piotr
AU - Kaidashev, Igor
AU - Kraxner, Helga
AU - Laune, Daniel
AU - Louis, Renaud
AU - Makris, Michael
AU - Monti, Riccardo
AU - Morais-Almeida, Mario
AU - M?sges, Ralph
AU - Niedoszytko, Marek
AU - Papadopoulos, Nikolaos G.
AU - Patella, Vincenzo
AU - Pham-Thi, Nh?n
AU - Regateiro, Frederico S.
AU - Reitsma, Sietze
AU - Rouadi, Philip W.
AU - Samolinski, Boleslaw
AU - Sheikh, Aziz
AU - Sova, Milan
AU - Taborda-Barata, Luis
AU - Toppila-Salmi, Sanna
AU - Sastre, Joaquin
AU - Tsiligianni, Ioanna
AU - Valiulis, Arunas
AU - Yorgancioglu, Arzu
AU - Zidarn, Mihaela
AU - Zuberbier, Torsten
AU - Fonseca, Joao A.
AU - Bousquet, Jean
N1 - Funding Information: MASK-air has been supported by Charité Universitätsmedizin Berlin , EU grants (EU Structural and Development Funds; POLLAR, EIT Health, Twinning, EIP on AHA and H2020) and educational grants from Mylan-Viatris, ALK, GSK, Novartis , and Uriach. Publisher Copyright: © 2022 American Academy of Allergy, Asthma & Immunology
PY - 2023/4
Y1 - 2023/4
N2 - Background: In clinical and epidemiological studies, cutoffs of patient-reported outcome measures can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (VAS) cutoffs in MASK-air have not been tested. Objective: To calculate cutoffs for VAS global, nasal, ocular, and asthma symptoms. Methods: In a cross-sectional study design of all MASK-air participants, we compared (1) approaches based on the percentiles (tertiles or quartiles) of VAS distributions and (2) data-driven approaches based on clusters of data from 2 comparators (VAS work and VAS sleep). We then performed sensitivity analyses for individual countries and for VAS levels corresponding to full allergy control. Finally, we tested the different approaches using MASK-air real-world cross-sectional and longitudinal data to assess the most relevant cutoffs. Results: We assessed 395,223 days from 23,201 MASK-air users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cutoff values than the data-driven approach. We obtained consistent results in the data-driven approach. Following the latter, the proposed cutoff differentiating ?controlled? and ?partly-controlled? patients was similar to the cutoff value that had been arbitrarily used (20/100). However, a lower cutoff was obtained to differentiate between ?partly-controlled? and ?uncontrolled? patients (35 vs the arbitrarily-used value of 50/100). Conclusions: Using a data-driven approach, we were able to define cutoff values for MASK-air VASs on allergy and asthma symptoms. This may allow for a better classification of patients with rhinitis and asthma according to different levels of control, supporting improved disease management.
AB - Background: In clinical and epidemiological studies, cutoffs of patient-reported outcome measures can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (VAS) cutoffs in MASK-air have not been tested. Objective: To calculate cutoffs for VAS global, nasal, ocular, and asthma symptoms. Methods: In a cross-sectional study design of all MASK-air participants, we compared (1) approaches based on the percentiles (tertiles or quartiles) of VAS distributions and (2) data-driven approaches based on clusters of data from 2 comparators (VAS work and VAS sleep). We then performed sensitivity analyses for individual countries and for VAS levels corresponding to full allergy control. Finally, we tested the different approaches using MASK-air real-world cross-sectional and longitudinal data to assess the most relevant cutoffs. Results: We assessed 395,223 days from 23,201 MASK-air users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cutoff values than the data-driven approach. We obtained consistent results in the data-driven approach. Following the latter, the proposed cutoff differentiating ?controlled? and ?partly-controlled? patients was similar to the cutoff value that had been arbitrarily used (20/100). However, a lower cutoff was obtained to differentiate between ?partly-controlled? and ?uncontrolled? patients (35 vs the arbitrarily-used value of 50/100). Conclusions: Using a data-driven approach, we were able to define cutoff values for MASK-air VASs on allergy and asthma symptoms. This may allow for a better classification of patients with rhinitis and asthma according to different levels of control, supporting improved disease management.
KW - Asthma
KW - Conjunctivitis
KW - Cutoffs
KW - MASK-air
KW - Rhinitis
UR - http://www.scopus.com/inward/record.url?scp=85146860940&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jaip.2022.12.005
DO - https://doi.org/10.1016/j.jaip.2022.12.005
M3 - Article
C2 - 36566778
SN - 2213-2198
VL - 11
SP - 1281-1289.e5
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 4
ER -